[Biochemical principles of the development of new cardiac drugs of the digitalis type].
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000284:Administration, Oral; D000818:Animals; D001711:Biotransformation; D001923:Brain Chemistry; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000378:metabolism*; D002415:Cats; D004074:Digitoxin / Q000032:analysis / Q000097:blood / Q000378:metabolism; D004077:Digoxin / Q000097:blood; D004285:Dogs; D004386:Duodenum; D006207:Half-Life; D006801:Humans; D007267:Injections; D007700:Kinetics; D007799:Lanatosides / Q000008:administration & dosage; D051379:Mice; D009206:Myocardium / Q000032:analysis; D011817:Rabbits; D051381:Rats; D013045:Species Specificity; D013329:Structure-Activity Relationship
D002301:Cardiac Glycosides; D007799:Lanatosides; D004077:Digoxin; D004074:Digitoxin; D000251:Adenosine Triphosphatases
Biochemische Grundlagen der Entwicklung neuartiger Herzmittel des Digitalistyps.